Difference between revisions of "Team:Shenzhen SFLS"

(Prototype team page)
Line 1: Line 1:
 
{{Shenzhen_SFLS}}
 
{{Shenzhen_SFLS}}
 
<html>
 
<html>
<h2> Welcome to iGEM 2015! </h2>
+
<h2> Welcome to iGEM Shenzhen_SFLS!
<p>Your team has been approved and you are ready to start the iGEM season! </p>
+
<br />
 
+
<br />
<h4>Before you start: </h4>
+
Project at a glimpse:
<p> Please read the following pages:</p>
+
  </h2>
<ul>
+
<li> <a href="https://2015.igem.org/Requirements">Requirements page </a> </li>
+
<li> <a href="https://2015.igem.org/Wiki_How-To">Wiki Requirements page</a></li>
+
</ul>
+
  
 
<div class="highlightBox">
 
<div class="highlightBox">
<h4> Styling your wiki </h4>
+
<br />
<p>You may style this page as you like or you can simply leave the style as it is. You can easily keep the styling and edit the content of these default wiki pages with your project information and completely fulfill the requirement to document your project.</p>
+
This year Shenzhen_SFLS aims to build a system connected to the interactions between antibody and antigen and to apply it to a brand new cancer therapy called CAR-T cell. Using synthetic biological way, we constructed a fused protein which was divided into three parts: an antigen tag, a flexible linker peptide and a medication molecule with the effect of destroying the targeted cell. Instead of the traditional method of improving the antibody’s affinity, we were just trying to reflect reversely and weaken the interactions to build this system.
<p>While you may not win Best Wiki with this styling, your team is still eligible for all other awards. This default wiki meets the requirements, it improves navigability and ease of use for visitors, and you should not feel it is necessary to style beyond what has been provided.</p>
+
<br/>
 +
Our system complies with a simple logic rule that the antigen tag will constantly adhere to the antibody unless the targeted antigen appears. The tag is mutated from the original antigen so that it will have less hydrogen bond binding sites and weaker interaction with the antibody. Since a linker and a sort of medication are linked to the antigen tag, when it separates from the antibody, the medication can become effective immediately.
 +
<br/>
 +
After zooming in for further information about cancer therapy, we soon gained sufficient information of the most effective cancer therapy of this age called CAR-T cell. Chimeric antigen T cell therapy combines inborn immune reaction with synthetic biological method which can help T cells eliminate the interferences released by cancerous cells. Supplementary information of this therapy will be given in other parts of our wiki.
 +
<br/>
 +
We hope to be able to apply our project to cancer treatment for several reasons. How to defeat cancer remains an important worldwide problem and every day similar tragedies happen to our friends and families, classmates and teachers, leaving permanent scars on our souls. Young as we are, we hope to be able to make our own contributions to this issue. It cannot be neglected that our project acts as a guided missile against cancer and dramatically increases the lethality of CAR-T cells. In conclusion, our project has both realistic significance and academic value, and we will strive to achieve further accomplishments in this field.
 
</div>
 
</div>
 
<h4> Editing your wiki </h4>
 
<p>On this page you can document your project, introduce your team members, document your progress and share your iGEM experience with the rest of the world! </p>
 
<p> <a href="https://2015.igem.org/wiki/index.php?title=Team:Shenzhen_SFLS&action=edit"> Click here to edit this page! </a></p>
 
<p>See tips on how to edit your wiki on the <a href="https://2015.igem.org/TemplatesforTeams_Code_Documentation">Template Documentation</a> page.</p>
 
 
 
<h4>Templates </h4>
 
<p> This year we have created templates for teams to use freely. More information on how to use and edit the templates can be found on the
 
<a href="https://2015.igem.org/TemplatesforTeams_Code_Documentation">Template Documentation </a> page.</p>
 
 
 
<h4>Tips</h4>
 
<p>This wiki will be your team’s first interaction with the rest of the world, so here are a few tips to help you get started: </p>
 
<ul>
 
<li>State your accomplishments! Tell people what you have achieved from the start. </li>
 
<li>Be clear about what you are doing and how you plan to do this.</li>
 
<li>You have a global audience! Consider the different backgrounds that your users come from.</li>
 
<li>Make sure information is easy to find; nothing should be more than 3 clicks away.  </li>
 
<li>Avoid using very small fonts and low contrast colors; information should be easy to read.  </li>
 
<li>Start documenting your project as early as possible; don’t leave anything to the last minute before the Wiki Freeze. For a complete list of deadlines visit the <a href="https://2015.igem.org/Calendar_of_Events">iGEM 2015 calendar</a> </li>
 
<li>Have lots of fun! </li>
 
</ul>
 
 
 
<h4>Inspiration</h4>
 
<p> You can also view other team wikis for inspiration! Here are some examples:</p>
 
<ul>
 
<li> <a href="https://2014.igem.org/Team:SDU-Denmark/"> 2014 SDU Denmark </a> </li>
 
<li> <a href="https://2014.igem.org/Team:Aalto-Helsinki">2014 Aalto-Helsinki</a> </li>
 
<li> <a href="https://2014.igem.org/Team:LMU-Munich">2014 LMU-Munich</a> </li>
 
<li> <a href="https://2014.igem.org/Team:Michigan"> 2014 Michigan</a></li>
 
<li> <a href="https://2014.igem.org/Team:ITESM-Guadalajara">2014 ITESM-Guadalajara </a></li>
 
<li> <a href="https://2014.igem.org/Team:SCU-China"> 2014 SCU-China </a></li>
 
</ul>
 
 
<h4> Uploading pictures and files </h4>
 
<p> You can upload your pictures and files to the iGEM 2015 server. Remember to keep all your pictures and files within your team's namespace or at least include your team's name in the file name. <br />
 
When you upload, set the "Destination Filename" to <code>Team:YourOfficialTeamName/NameOfFile.jpg</code>. (If you don't do this, someone else might upload a different file with the same "Destination Filename", and your file would be erased!)</p>
 
 
<a href="https://2015.igem.org/Special:Upload">CLICK HERE TO UPLOAD FILES</a>
 
 
  
  

Revision as of 14:56, 15 July 2015

Welcome to iGEM Shenzhen_SFLS!

Project at a glimpse:


This year Shenzhen_SFLS aims to build a system connected to the interactions between antibody and antigen and to apply it to a brand new cancer therapy called CAR-T cell. Using synthetic biological way, we constructed a fused protein which was divided into three parts: an antigen tag, a flexible linker peptide and a medication molecule with the effect of destroying the targeted cell. Instead of the traditional method of improving the antibody’s affinity, we were just trying to reflect reversely and weaken the interactions to build this system.
Our system complies with a simple logic rule that the antigen tag will constantly adhere to the antibody unless the targeted antigen appears. The tag is mutated from the original antigen so that it will have less hydrogen bond binding sites and weaker interaction with the antibody. Since a linker and a sort of medication are linked to the antigen tag, when it separates from the antibody, the medication can become effective immediately.
After zooming in for further information about cancer therapy, we soon gained sufficient information of the most effective cancer therapy of this age called CAR-T cell. Chimeric antigen T cell therapy combines inborn immune reaction with synthetic biological method which can help T cells eliminate the interferences released by cancerous cells. Supplementary information of this therapy will be given in other parts of our wiki.
We hope to be able to apply our project to cancer treatment for several reasons. How to defeat cancer remains an important worldwide problem and every day similar tragedies happen to our friends and families, classmates and teachers, leaving permanent scars on our souls. Young as we are, we hope to be able to make our own contributions to this issue. It cannot be neglected that our project acts as a guided missile against cancer and dramatically increases the lethality of CAR-T cells. In conclusion, our project has both realistic significance and academic value, and we will strive to achieve further accomplishments in this field.